{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:03:04Z","timestamp":1777730584242,"version":"3.51.4"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011284","name":"Valeant","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.pcad.2020.12.008","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T11:40:11Z","timestamp":1609155611000},"page":"65-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors"],"prefix":"10.1016","volume":"67","author":[{"given":"Barbara","family":"Cybulska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longina","family":"K\u0142osiewicz-Latoszek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2020.12.008_bb0005","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0010","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0015","first-page":"1","article-title":"An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity","volume":"10","author":"Mo\u015fteoru","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0020","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11883-013-0388-7","article-title":"How low LDL-C should we go with statin therapy?","volume":"16","author":"Kostis","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.pcad.2020.12.008_bb0025","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0030","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss function mutations in PCSK9 and identification of compared heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pcad.2020.12.008_bb0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2020.12.008_bb0040","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.recesp.2017.03.031","article-title":"The zero-LDL hypothesis. Towards extremely low LDL concentrations. Scientific letter","volume":"71","author":"Masana","year":"2018","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacl.2017.12.018","article-title":"Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels \u2013 the zero-LDL hypothesis","volume":"12","author":"Masana","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0050","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/joim.12614","article-title":"Can LDL cholesterol be to low? Possible risks of extremely low levels","volume":"281","author":"Olsson","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2362.2006.01597.x","article-title":"Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system","volume":"36","author":"Parini","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pcad.2020.12.008_bb0060","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1194\/jlr.P058842","article-title":"Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients","volume":"56","author":"Apro","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pcad.2020.12.008_bb0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pcad.2020.12.008_bb0070","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1073\/pnas.87.9.3469","article-title":"Low density lipoprotein receptor-binding activity in human tissues: quantitavie importance of hepatic receptors and evidence of regulations of their expression in vivo","volume":"87","author":"Rudling","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pcad.2020.12.008_bb0075","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI114245","article-title":"Immunohistochemical localization of low density lipoprotein receptors in adrenal gland, liver and intestine","volume":"84","author":"Fong","year":"1989","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.pcad.2020.12.008_bb0080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jacl.2019.05.006","article-title":"Low LDL cholesterol \u2013 friend or foe","volume":"13","author":"Hegele","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0085","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insight and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2020.12.008_bb0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2265.1986.tb01702.x","article-title":"Pattern of plasma levels of cortisol, dehydroepiandrasterone and pregenolone sulphate in normal subjects and in homozygous familial hypercholesterolaemia during ACTH infusion","volume":"25","author":"Boizel","year":"1986","journal-title":"Clin Edocrinol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pharmthera.2016.11.001","article-title":"Intensive LDL-cholesterol lowering therapy and neurocognitive function","volume":"170","author":"Banach","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pcad.2020.12.008_bb0100","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","article-title":"Brain cholesterol: long secret life behind the barrier","volume":"24","author":"Bj\u04e7rkhem","year":"2004","journal-title":"Atheroscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0105","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1212\/WNL.56.12.1683","article-title":"Middlife vascular factors and late-life mild cognitive improvement: a population based study","volume":"56","author":"Kivipelto","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pcad.2020.12.008_bb0110","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s10072-020-04243-6","article-title":"The efficacy of statins in the treatment of Alzheimer's disease: a meta-analysis of randomized controlled trial","volume":"41","author":"Xuan","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.pcad.2020.12.008_bb0115","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.20160534","article-title":"27-Hydroxy-cholesterol impaires neuronal up-take through an IRAP\/GLUT4 system dysregulation","volume":"214","author":"Ismail","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bbr.2014.10.018","article-title":"27-Hydroxy-cholesterol mediates negative effects of dietary cholesterol on cognition in mice","volume":"278","author":"Heverin","year":"2015","journal-title":"Behav Brain Res"},{"issue":"11","key":"10.1016\/j.pcad.2020.12.008_bb0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25675","article-title":"Statins and LDL-C in secondary prevention: so much progress, so far to go","volume":"3","author":"Banach","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pcad.2020.12.008_bb0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5603\/KP.a2019.0017","article-title":"Landmark studies on coronary heart disease epidemiology. The Framingham heart study after 70 years and seven countries years after 50 years","volume":"77","author":"Cybulska","year":"2019","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0135","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(86)90597-0","article-title":"Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men","volume":"2","author":"Martin","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.12.008_bb0140","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions, the atherosclerosis risk in communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.12.008_bb0145","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0140-6736(05)67767-7","article-title":"Nature's randomized trials","volume":"366","author":"Hingerani","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.12.008_bb0150","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2020.12.008_bb0155","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/eurheartj\/ehx462","article-title":"How to use Mendelian randomization to anticipate the results of randomized trials","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2020.12.008_bb0160","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low density lipoprotein cholesterol beginning early life on the risk of coronary heart disease","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2020.12.008_bb0165","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12916-020-01792-7","article-title":"LDL-C: lower is better for longer-even at low risk","volume":"18","author":"Penson","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0170","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.12659\/MSM.890845","article-title":"Assessment of the relationship between lipid parameters and obesity indices in non-diabetic obese patients: a preliminary report","volume":"20","author":"St\u0119pie\u0144","year":"2014","journal-title":"Med Sci Monit"},{"issue":"10113","key":"10.1016\/j.pcad.2020.12.008_bb0175","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pcad.2020.12.008_bb0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11886-019-1160-6","article-title":"Low density lipoprotein cholesterol after an acute coronary syndrome: how low to go?","volume":"21","author":"Qamar","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.pcad.2020.12.008_bb0185","first-page":"1883","article-title":"Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.12.008_bb0190","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0195","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III)","volume":"285","author":"Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2020.12.008_bb0200","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent event trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.12.008_bb0210","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European guidelines on cardiovascular disease prevention in clinical practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2020.12.008_bb0215","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0225","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low density lipoprotein be to low? The safety and efficacy of achieving very low density lipoprotein with intensive statin therapy: a PROVE IT \u2013 TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Study (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"suppl 2","key":"10.1016\/j.pcad.2020.12.008_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.pcad.2020.12.008_bb0240","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a pre-specified analysis of IMPROVE Trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0245","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very LDL-cholesterol concentrations with PCSK9 inhibitor evolocumab: a prespecified secondary analysis of FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.12.008_bb0250","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and risk for cardiovascular events. A meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0255","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low density lipoprotein cholesterol in patients starting with very low levels","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0260","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for prevention of major vascular events: a systematic review and meta-analysis of randomized trials including 327 037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.pcad.2020.12.008_bb0265","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/HCO.0000000000000305","article-title":"IMPROVE-IT: what have we learned?","volume":"31","author":"Banach","year":"2016","journal-title":"Curr Opin Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2020.12.008_bb0270","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1517\/14656566.2016.1118055","article-title":"Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options","volume":"17","author":"Serban","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.pcad.2020.12.008_bb0275","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cvr\/cvy301","article-title":"What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?","volume":"115","author":"Banach","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.pcad.2020.12.008_bb0280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pcad.2020.04.004","article-title":"What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?","volume":"63","author":"Cybulska","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.pcad.2020.12.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014129","article-title":"Effect of evolocumab on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a): a pooled analysis of phase 2 and phase 3 studies","volume":"9","author":"Toth","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2020.12.008_bb0290","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MED.0000000000000317","article-title":"Plaque burden microstructures and compositions under-achieving very low LDL-C levels","volume":"24","author":"Kataoka","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.pcad.2020.12.008_bb0295","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MED.0000000000000234","article-title":"Regression of coronary atheroma with statin therapy","volume":"23","author":"Elzhazly","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.pcad.2020.12.008_bb0300","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.12.008_bb0305","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0310","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients. The GLAGOV randomized trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2020.12.008_bb0315","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12916-015-0459-4","article-title":"Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studiem","volume":"13","author":"Banach","year":"2015","journal-title":"BMC Med"},{"issue":"17","key":"10.1016\/j.pcad.2020.12.008_bb0320","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition","volume":"72","author":"Nicholls","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2020.12.008_bb0325","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints","volume":"70","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0330","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.03.102","volume":"100","author":"LaRosa","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0335","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low density lipoprotein cholesterol level with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0340","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","article-title":"Effects of evolocumab on vitamin E and steroid hormone levels: results from 52-week phase 3. double-blind, randomized, placebo-controlled DESCARTES Study","volume":"177","author":"Blom","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2020.12.008_bb0345","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2020.12.008_bb0350","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomized controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0355","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 Studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"issue":"11, Suppl. 1","key":"10.1016\/j.pcad.2020.12.008_bb0360","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/S0735-1097(20)32707-8","article-title":"Relationship between low-density lipoprotein cholesterol, lipid lowering agents and the risk of stroke: a meta-analysis of observational studies and randomized controlled trials","volume":"75","author":"Banach","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0365","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"Effect of alirocumab on stroke in Odyssey outcomes","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.12.008_bb0370","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin 9 sarine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a net-work meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2020.12.008_bb0375","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pcad.2020.12.008_bb0380","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacl.2018.05.012","article-title":"PCSK9 and neurocognitive function: should it be still an issue after Fourier and Ebbinghaus results?","volume":"12","author":"Mannarino","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0385","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","article-title":"Cognition after lowering LDL-cholesterol with evolocumab","volume":"75","author":"Gencer","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2020.12.008_bb0390","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5114\/aoms.2020.93253","article-title":"2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders","volume":"16","author":"Solnica","year":"2020","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pcad.2020.12.008_bb0395","article-title":"Lipid disorders therapy in patients with chronic coronary syndrome and myocardial infarction. Experts Opinion of the Polish Society of Cardiology (PCS) and the Polish Lipid Associatin (PoLA)","author":"Dyrbus","year":"2020","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.pcad.2020.12.008_bb0400","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"Int J Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062020302103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062020302103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:19:26Z","timestamp":1758500366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062020302103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":80,"alternative-id":["S0033062020302103"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2020.12.008","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2020.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}